Alto Neuroscience (ANRO) Other Operating Expenses (2023)

Alto Neuroscience's (ANRO) quarterly Other Operating Expenses came in at $30.1 million in Q4 2023.

Alto Neuroscience (ANRO) Other Operating Expenses (2023) Analysis & Trends

Alto Neuroscience has disclosed Other Operating Expenses across 1 years of filings, most recently posting $30.1 million for Q4 2023.

Other Operating Expenses for Q4 2023 came in at $30.1 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $30.1 million (changed N/A YoY), and the FY2023 annual result was $30.1 million, changed N/A from the prior year.
Other Operating Expenses came in at $30.1 million for Q4 2023 at Alto Neuroscience.
In the past five years, Other Operating Expenses ranged from a high of $30.1 million in Q4 2023 to a low of $30.1 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Alto Neuroscience	697.66 Mn	433.90 Mn	-

Download Data

Date	Value
Dec 31, 2023	30.09 Mn